Advanced progress of the relationship between PCSK9 monoclonal antibodies and hyperglycemic adverse events

Frontiers in Cardiovascular Medicine

Cardiovascular Medicine

Jing Zhao¹  Yu Peng¹  Yongxiang Wang¹  Zheng Zhang¹  Ruixing Zhang² 

[1] Department of Heart Center, The First Hospital of Lanzhou University, Lanzhou, China;Key Laboratory for Cardiovascular Diseases of Gansu Province, The First Hospital of Lanzhou University, Lanzhou, China;The First Clinical Medical College, Lanzhou University, Lanzhou, China;Department of Heart Center, The First Hospital of Lanzhou University, Lanzhou, China;Key Laboratory for Cardiovascular Diseases of Gansu Province, The First Hospital of Lanzhou University, Lanzhou, China;

关键词: proprotein convertase subtilisin/kexin type 9 monoclonal antibodies;    lipid metabolism;    hyperglycemic adverse events;    coronary heart disease;    type 2 diabetes mellitus;   

DOI  :  10.3389/fcvm.2023.1117143

 received in 2022-12-06, accepted in 2023-06-06,  发布年份 2023

来源: Frontiers

【 摘 要 】

Purpose of ReviewLong-term use of statins had been confirmed to cause an increase in hyperglycemic adverse events (HAEs), whose mechanism has been well understood. Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (PCSK9-mAbs), a kind of new lipid-lowering drug, can effectively reduce plasma low-density lipoprotein cholesterol levels in patients with CHD and have been widely used. However, animal experiments, Mendelian randomization studies, clinical researches and Meta-analyses which focused on the relationship between PCSK9-mAbs and HAEs had reached different conclusions, which has attracted great attention from clinicians.Recent FindingsThe newest FOURIER-OLE randomized controlled trial followed PCSK9-mAbs users for over 8 years, whose results suggested that long-term use of PCSK9-mAbs did not increase the incidence of HAEs. Newest Meta-analyses also indicated that there was no relationship between PCSK9-mAbs and NOD. Meanwhile, genetic polymorphisms and variants related to PCSK9 might have effects on HAEs.ConclusionAccording to the results of current studies, there is no significant relationship between PCSK9-mAbs and HAEs. However, longer-term follow-up studies are still needed to confirm it. Although PCSK9 genetic polymorphisms and variants may affect the possible occurrence of HAEs, there is no need to perform relevant genetic testing before applying PCSK9-mAbs.

【 授权许可】

Unknown   
© 2023 Zhang, Wang, Peng, Zhao and Zhang.